WE PACKED THE COURTROOM AT THE APPEAL HEARING, READ ALL ABOUT IT ON OUR ACT NOW PAGE
WE PACKED THE COURTROOM AT THE APPEAL HEARING, READ ALL ABOUT IT ON OUR ACT NOW PAGE
YOU SHOULD HAVE BY NOW RECEIVED YOUR "MEDICARE & YOU 2024" INFORMATIONAL BOOKLET IN THE MAIL. BELOW ARE SOME OF THE MAJOR POINTS OF THE BOOKLET. FOR ANYTHING DEALING WITH MEDICARE ADVANTAGE-THIS ISSUE IS STILL IN LIMBO. IT'S UP TO US TO STOP ANY POLITICIAN FROM STEALING OUR DEFINED BENEFIT. GO TO THE "ACT NOW" PAGE BY CLICKING ON "FIND OUT MORE" FOR MORE ON HOW TO PROTECT OUR HEALTHCARE-THANK YOU FOR YOUR SUPPORT!
Summary:
Details:
Leqembi is the only drug on the market right now that has demonstrated the ability to slow the progression of early stages of Alzheimer's disease in a clinical trial. The monoclonal antibody, administered twice monthly through intravenous means, slowed cognitive decline by 27% over 18 months in the trial.
Leqembi is made by Japanese drugmaker Eisai and its partner Biogen, which is based in Cambridge, Massachusetts.
Medicare's decision to cover Leqembi, which came moments after the Food and Drug Administration fully approved the drug Thursday, promises to make the treatment more accessible to patients.
Medicare coverage is crucial for most patients to have any hope of being able to afford Leqembi. Eisai has priced Leqembi at $26,500 per year before insurance coverage, which is extraordinarily expensive for Medicare patients, who have a median income of about $30,000.
Medicare is picking up the majority of the bill, though many patients will still face several thousand dollars in out-of-pocket costs.
Patients with traditional Medicare will pay 20% of the bill for Leqembi, according to the federal Centers for Medicare and Medicaid Services. That means these patients could see an annual bill of more than $5,000, according to an estimate from KFF, a nonprofit group that researches health-care issues.
People with Medicare Advantage plans also typically pay 20% for drugs such as Leqembi, up to their out-of-pocket maximum, which was about $5,000 on average for in-network services, according to KFF.
Patients with supplemental insurance such as Medigap or Medicaid might pay less, according to KFF.
People of modest means might not be able to afford the out-of-pocket costs for Leqembi even with Medicare coverage, said Tricia Neuman, an expert on Medicare at KFF.
TO READ THE WHOLE ARTICLE, click> Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know (msn.com)
,
The City will reimburse retirees and their eligible dependents for Medicare Part B premiums paid, excluding any penalties. You must be receiving a City pension check and be enrolled as the contract holder for City health benefits in order to receive reimbursement for Part B premiums. How do I get reimbursed for Medicare Part B premiums? What document do I need to submit to receive my correct Part B reimbursement amount? You must submit a copy of your Social Security benefits verification statement (your “New Benefit Amount”) or a copy of a 2022 Centers for Medicare and Medicaid Services
(CMS) billing statement.
>CLICK HERE TO GET TO KNOW WHAT THE PART B REIMBURSEMENT IS ALL ABOUT<
CLICK HERE TO DOWNLOAD THE 2022 RMD FORM
(IT IS ALSO VIEWABLE ON THE OLR PAGE)
Click on "FIND OUT MORE" below
It will bring you to the OLR Website,
Scroll down till you get to the Part B Reimbursement Form and Click
We can no longer provide a direct link due to restrictions placed
on the OLR Page.
Copyright © 2024 Retired Member's Association of the NYC Fire Dept. - All Rights Reserved.
Powered by GoDaddy